首页 | 本学科首页   官方微博 | 高级检索  
检索        

替硝唑片在健康志愿者体内的生物等效性研究
引用本文:杨丽莉,徐亚涛,邱相君.替硝唑片在健康志愿者体内的生物等效性研究[J].现代中西医结合杂志,2006,15(20):2752-2754.
作者姓名:杨丽莉  徐亚涛  邱相君
作者单位:1. 河南省洛阳市第一中医院,河南,洛阳,471002
2. 中铁十五局集团中心医院,河南,洛阳,471002
3. 河南科技大学医学院,河南,洛阳,471003
摘    要:目的研究替硝唑片的生物等效性。方法选择健康志愿者20例,用随机双交叉试验方法,单剂量口服替硝唑片的试验制剂和参比制剂,剂量分别为1 g,洗净期为2周;分别于服药后60 h内不同时间点抽取静脉血。用HPLC法测定血浆中替硝唑浓度,用DAS程序进行生物等效性评价。结果单剂量口服替硝唑片试验制剂和参比制剂后,血浆中替硝唑的Cmax分别为(20.49±2.03)mg/L和(19.99±2.37)mg/L;Tmax分别为(1.70±0.25)h和(1.73±0.26)h;T1/2分别为(16.06±1.77)h和(16.51±2.63)h;AUC(0-60)分别为(430.75±56.16)mg/(h.L)和(423.86±45.34)mg/(h.L);AUC(0-inf)分别为(468.47±63.04)mg/(h.L)和(462.32±42.70)mg/(h.L)。AUC(0-60)、AUC(0-inf)、Cmax的90%可信区间分别为99.69%~105.76%、98.61%~104.16%、97.79%~104.08%。相对生物利用度为(101.6±8.4)%。结论试验制剂与参比制剂具有生物学等效性。

关 键 词:替硝唑  药代动力学  相对生物利用度  生物等效性  高效液相色谱法
文章编号:1008-8849(2006)20-2752-03
收稿时间:2006-02-23
修稿时间:2006年2月23日

Study of the bioequivalence of Tinidazole tablets in healthy volunteers
YANG Li-li,XU Ya-tao,QIU Xiang-jun.Study of the bioequivalence of Tinidazole tablets in healthy volunteers[J].Modern Journal of Integrated Chinese Traditional and Western Medicine,2006,15(20):2752-2754.
Authors:YANG Li-li  XU Ya-tao  QIU Xiang-jun
Institution:YANG Li-li~1,XU Ya-tao~2,QIU Xiang-jun~3
Abstract:objective It is to study the relative bioavailability and bioequivalence of Tinidazole tablets in healthy volunteers.Methods A single oral doses(1g) of tested and reference preparations of Tinidazole were given to 20 healthy volunteers respectively in a randomised crossover study.The cleaning stage was 2 weeks.Venous blood was drawn at different times within 60h after taking medicine.The concentration of Tinidazole in plasma was determined by HPLC and the bioavailability and bioequivalence of two preparations were evaluated by DAS program.Results After a single oral doses of tested and reference preparations of Tinidazole,the pharmacokinetics parameters for Tinidazole were as follows: C_(max) were(20.49±2.03)mg/L and(19.99±2.37) mg/L;T_(max) were(1.70±0.25)h and (1.73±0.26)h;T_(1/2) were(16.06±1.77)h and(16.51±2.63)h;AUC_((0-60)) were(430.75±56.16)mg/(h·L) and(423.86±45.34) mg/(h·L);AUC_((0-inf)) were(468.47±63.04) mg/(h·L) and(462.32±42.70) mg/(h·L) for T and R respectively.The 90% confidential interval of C_(max),AUC_((0-60)) and AUC_((0-inf)) of tested formulation were 99.69%-105.76%,98.61%-104.16% and 97.79%-104.08% respectively.The relative bioavailability was(101.6±8.4)%.Conclusion The test and reference preparations both have bioequivalence.
Keywords:Tinidazole  pharmacokineties  relative bioavailability  bioequivalence  HPLC
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号